Linda R Duska

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer
    Linda R Duska
    Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 96:198-203. 2005
  2. ncbi request reprint Detection of female lower genital tract dysplasia using orally administered 5-aminolevulinic acid induced protoporphyrin IX: a preliminary study
    Linda R Duska
    Vincent Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Gynecol Oncol 85:125-8. 2002
  3. ncbi request reprint Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary
    Linda R Duska
    Vincent Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Gynecol Oncol 85:459-63. 2002
  4. ncbi request reprint Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo
    Robert L DeBernardo
    Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer Biol Ther 4:103-7. 2005
  5. doi request reprint Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
    Ursula A Matulonis
    Department of Medical Oncology, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston MA 02115, USA
    J Clin Oncol 26:5761-6. 2008
  6. ncbi request reprint Phase II trial of anastrozole in women with asymptomatic müllerian cancer
    Marcela G del Carmen
    Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 91:596-602. 2003
  7. ncbi request reprint Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma
    Ramey D Littell
    Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 103:570-4. 2006
  8. ncbi request reprint Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors
    Susanna M Campos
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Gynecol Oncol 90:610-8. 2003
  9. ncbi request reprint Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma
    Ami P Vaidya
    Division of Gynecologic Oncology, Gillette Center for Women s Cancers, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 103:684-7. 2006
  10. doi request reprint When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes
    Linda R Duska
    Division of Gynecologic Oncology, University of Virginia Health Systems, Charlottesville, VA 22903, USA
    Gynecol Oncol 116:374-7. 2010

Collaborators

Detail Information

Publications24

  1. ncbi request reprint A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer
    Linda R Duska
    Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 96:198-203. 2005
    ..To determine the toxicity, tolerability, and feasibility of delivering combination chemotherapy with subsequent radiation therapy to women with high-risk endometrial cancer and to evaluate the long-term bowel toxicity of this regimen...
  2. ncbi request reprint Detection of female lower genital tract dysplasia using orally administered 5-aminolevulinic acid induced protoporphyrin IX: a preliminary study
    Linda R Duska
    Vincent Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Gynecol Oncol 85:125-8. 2002
    ..The current study was undertaken to demonstrate the feasibility of administering ALA by mouth (po) with the hypothesis that systemic administration might provide a more reliable diagnostic tool...
  3. ncbi request reprint Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary
    Linda R Duska
    Vincent Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Gynecol Oncol 85:459-63. 2002
    ..The current study was undertaken to characterize a group of patients treated as if they had aggressive epithelial ovarian tumors, with cytoreductive surgery and combination paclitaxel/platinum chemotherapy...
  4. ncbi request reprint Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo
    Robert L DeBernardo
    Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer Biol Ther 4:103-7. 2005
    ..Collectively these results suggest that Cables is an important regulator of cell proliferation and loss of Cables expression contributes to the development of all types of EC...
  5. doi request reprint Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
    Ursula A Matulonis
    Department of Medical Oncology, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston MA 02115, USA
    J Clin Oncol 26:5761-6. 2008
    ..Pemetrexed is a multitargeted antifolate with manageable toxicity and has been combined with carboplatin to treat other cancers...
  6. ncbi request reprint Phase II trial of anastrozole in women with asymptomatic müllerian cancer
    Marcela G del Carmen
    Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 91:596-602. 2003
    ..To evaluate the efficacy and toxicity of the selective aromatase inhibitor anastrozole (Arimidex), we conducted a phase II trial in 53 women with asymptomatic recurrent/persistent müllerian cancer...
  7. ncbi request reprint Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma
    Ramey D Littell
    Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 103:570-4. 2006
    ....
  8. ncbi request reprint Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors
    Susanna M Campos
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Gynecol Oncol 90:610-8. 2003
    ..Ortho-Biotech) and paclitaxel (Taxol, Bristol Myers Squibb) are both active against Müllerian malignancies. A phase II trial was performed to determine the toxicity and efficacy of these agents when administered in combination...
  9. ncbi request reprint Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma
    Ami P Vaidya
    Division of Gynecologic Oncology, Gillette Center for Women s Cancers, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 103:684-7. 2006
    ..The current study was undertaken to compare outcomes, stage for stage, of uterine MMMT with poor prognosis endometrial adenocarcinomas...
  10. doi request reprint When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes
    Linda R Duska
    Division of Gynecologic Oncology, University of Virginia Health Systems, Charlottesville, VA 22903, USA
    Gynecol Oncol 116:374-7. 2010
    ....
  11. ncbi request reprint Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism
    Lisa Lee
    Division of Gynecologic Oncology, Biostatistics Center, Massachusetts General Hospital, Boston, USA
    J Reprod Med 54:133-8. 2009
    ..To document the rate of clinically significant venous thromboembolism (VTE) in patients with clear cell carcinoma of the endometrium (CCC-E)...
  12. ncbi request reprint Fertility-sparing surgery for ovarian low malignant potential tumors
    Gautam G Rao
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, J7 124, Dallas, TX 75390 9032, USA
    Gynecol Oncol 98:263-6. 2005
    ..Conservative management usually involves leaving behind the uterus and contralateral adnexa to allow future childbearing. The purpose of this study was to determine the outcome of women treated with fertility-sparing surgery...
  13. doi request reprint Abdominal radical trachelectomy: Success and pitfalls in a general gynecologic oncology practice
    Alexander Olawaiye
    Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 112:506-10. 2009
    ..To report our successes and complications with a series of abdominal radical trachelectomies performed to preserve fertility in young women at the Massachusetts General Hospital (MGH)...
  14. doi request reprint SGO White Paper on ovarian cancer: etiology, screening and surveillance
    John O Schorge
    Massachusetts General Hospital, Boston, MA, USA
    Gynecol Oncol 119:7-17. 2010
    ..CA125 is currently the only biomarker recommended for monitoring of therapy as well as detection of recurrence. This commentary provides an overview on the background, screening and surveillance of ovarian cancer...
  15. ncbi request reprint Advances in the surgical management of ovarian cancer
    Neil S Horowitz
    Department Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Reprod Med 50:454-66. 2005
    ..Further work needs to be undertaken in screening, prevention, surgery and adjuvant therapy...
  16. ncbi request reprint Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy
    Robert L DeBernardo
    Divisions of Gynecologic Oncology and Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Obstet Gynecol 105:1006-11. 2005
    ..To compare the efficacy of dalteparin, a low-molecular-weight heparin, to unfractionated heparin (UFH) in the prevention of deep venous thrombosis (DVT) and pulmonary embolism in patients after surgery for gynecologic malignancy...
  17. doi request reprint The Patient Protection and Affordable Care Act: what every provider of gynecologic oncology care should know
    Linda R Duska
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA
    Gynecol Oncol 129:606-12. 2013
    ....
  18. ncbi request reprint Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia--a pilot study
    Elizabeth Suh-Burgmann
    Divisions of Gynecologic Oncology and Hematology Oncology, Massachusetts General Hospital, Boston, Mass, USA
    Gynecol Obstet Invest 55:25-31. 2003
    ..The results suggest that intravaginal DHEA is safe and well tolerated and may promote regression of low-grade cervical lesions. Further study is needed to establish efficacy...
  19. ncbi request reprint Loss of cables, a cyclin-dependent kinase regulatory protein, is associated with the development of endometrial hyperplasia and endometrial cancer
    Lawrence R Zukerberg
    Departments of Pathology and Urology, Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer Res 64:202-8. 2004
    ..In addition, loss or suppression of Cables may be an early step in the development of endometrial cancer...
  20. ncbi request reprint Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma
    Jayanthi S Lea
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9032, USA
    Gynecol Oncol 91:558-62. 2003
    ..The purpose of this study was to identify poor prognostic factors of low-risk stage IB1 cervical adenocarcinoma..
  21. ncbi request reprint Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection
    Jayanthi S Lea
    Division of Gynecologic Oncology, University of Texas Southwestern, Dallas, Texas 75390, USA
    Gynecol Oncol 84:285-8. 2002
    ..The purpose of this study was to further define the node of para-aortic lymph node dissection in early-stage cervical adenocarcinoma treated by surgical intent...
  22. ncbi request reprint Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences
    Robert A Soslow
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 31:979-87. 2007
    ....
  23. ncbi request reprint Surgical staging of ovarian low malignant potential tumors
    Gautam G Rao
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Obstet Gynecol 104:261-6. 2004
    ..The purpose of this study was to compare the outcome of surgically staged patients with low malignant potential tumors with those who were not staged...
  24. ncbi request reprint Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival
    Jayanthi S Lea
    University of Texas Southwestern Medical Center, Dallas, Texas 75390 9032, USA
    Gynecol Oncol 84:115-9. 2002
    ..Few reports have described the outcome of patients with advanced cervical adenocarcinoma. The purpose of this study was to determine the prognostic factors and survival for patients with stage IIB-IVB disease...